ReP USP - Resultado da busca

Artigo de periodico
Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics (2022)
Pavan, Marcella; Yamamoto, Priscila; Silva, Rodrigo Moreira da; Salgado Junior, Wilson; Santos, José dos; Kemp, Rafael; Sankarankutty, Ajith Kumar ; Moraes, Natália de; Gaitani, Cristiane de
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP
Subjects: QUIMIOMETRIA, CROMATOGRAFIA LÍQUIDA, ESPECTROMETRIA DE MASSAS, REPRODUTIBILIDADE DE RESULTADOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAVAN, Marcella et al. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, v. 1205, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2022.123338. Acesso em: 09 nov. 2024.
APA
Pavan, M., Yamamoto, P., Silva, R. M. da, Salgado Junior, W., Santos, J. dos, Kemp, R., et al. (2022). Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, 1205. doi:10.1016/j.jchromb.2022.123338
NLM
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Vancouver
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 09 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control (2021)
Angelo, Marilene Lopes; Moreira, Fernanda de Lima ; Santos, Ana Laura Araújo; Salgado, Hérida Regina Nunes; Araújo, Magali Benjamim de
Source: Current Pharmaceutical Analysis. Unidade: FCFRP
Subjects: TERAPIA DA REPOSIÇÃO HORMONAL, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANGELO, Marilene Lopes et al. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control. Current Pharmaceutical Analysis, v. 17, n. 1, p. 31-39, 2021Tradução . . Disponível em: https://doi.org/10.2174/1573412916666191025143214. Acesso em: 09 nov. 2024.
APA
Angelo, M. L., Moreira, F. de L., Santos, A. L. A., Salgado, H. R. N., & Araújo, M. B. de. (2021). A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control. Current Pharmaceutical Analysis, 17( 1), 31-39. doi:10.2174/1573412916666191025143214
NLM
Angelo ML, Moreira F de L, Santos ALA, Salgado HRN, Araújo MB de. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control [Internet]. Current Pharmaceutical Analysis. 2021 ; 17( 1): 31-39.[citado 2024 nov. 09 ] Available from: https://doi.org/10.2174/1573412916666191025143214
Vancouver
Angelo ML, Moreira F de L, Santos ALA, Salgado HRN, Araújo MB de. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control [Internet]. Current Pharmaceutical Analysis. 2021 ; 17( 1): 31-39.[citado 2024 nov. 09 ] Available from: https://doi.org/10.2174/1573412916666191025143214
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 09 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 09 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Subjects: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 09 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics (2020)
Pinto, Leonardo Santos Ribeiro; Moreira, Fernanda de Lima ; Nardotto, Glauco Henrique Balthazar ; Cavalli, Ricardo de Carvalho ; Moisés, Elaine Christine Dantas ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTIDEPRESSIVOS, FARMACOCINÉTICA, GRAVIDEZ, ESTUDOS DE CASOS E CONTROLES, MUCOSA INTESTINAL, ANTI-HISTAMÍNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, v. 37, n. 7, 2020Tradução . . Disponível em: https://doi.org/10.1007/s11095-020-02854-4. Acesso em: 09 nov. 2024.
APA
Pinto, L. S. R., Moreira, F. de L., Nardotto, G. H. B., Cavalli, R. de C., Moisés, E. C. D., Duarte, G., & Lanchote, V. L. (2020). Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, 37( 7). doi:10.1007/s11095-020-02854-4
NLM
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 09 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Vancouver
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 09 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Artigo de periodico
A possible solution to model nonlinearity in elimination and distributional clearances with α2-adrenergic receptor agonists: example of the intravenous detomidine and methadone combination in sedated horses (2019)
Gozalo-Marcilla, Miguel ; Silva, Rodrigo Moreira da ; Luna, Stélio Pacca Loureiro ; Oliveira, Alice Rodrigues de; Fonseca, Mariana Werneck ; Lopes, Norberto Peporine ; Taylor, Polly M.; Pelligand, Ludovic
Source: Journal of Veterinary Pharmacology and Therapeutics. Unidade: FCFRP
Subjects: RECEPTORES ADRENÉRGICOS, ÓPIO, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOZALO-MARCILLA, Miguel et al. A possible solution to model nonlinearity in elimination and distributional clearances with α2-adrenergic receptor agonists: example of the intravenous detomidine and methadone combination in sedated horses. Journal of Veterinary Pharmacology and Therapeutics, v. 42, p. 738-744, 2019Tradução . . Disponível em: https://doi.org/10.1111/jvp.12815. Acesso em: 09 nov. 2024.
APA
Gozalo-Marcilla, M., Silva, R. M. da, Luna, S. P. L., Oliveira, A. R. de, Fonseca, M. W., Lopes, N. P., et al. (2019). A possible solution to model nonlinearity in elimination and distributional clearances with α2-adrenergic receptor agonists: example of the intravenous detomidine and methadone combination in sedated horses. Journal of Veterinary Pharmacology and Therapeutics, 42, 738-744. doi:10.1111/jvp.12815
NLM
Gozalo-Marcilla M, Silva RM da, Luna SPL, Oliveira AR de, Fonseca MW, Lopes NP, Taylor PM, Pelligand L. A possible solution to model nonlinearity in elimination and distributional clearances with α2-adrenergic receptor agonists: example of the intravenous detomidine and methadone combination in sedated horses [Internet]. Journal of Veterinary Pharmacology and Therapeutics. 2019 ; 42 738-744.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1111/jvp.12815
Vancouver
Gozalo-Marcilla M, Silva RM da, Luna SPL, Oliveira AR de, Fonseca MW, Lopes NP, Taylor PM, Pelligand L. A possible solution to model nonlinearity in elimination and distributional clearances with α2-adrenergic receptor agonists: example of the intravenous detomidine and methadone combination in sedated horses [Internet]. Journal of Veterinary Pharmacology and Therapeutics. 2019 ; 42 738-744.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1111/jvp.12815
Artigo de periodico
Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac (2017)
Silva, Carolina de Miranda; Rocha, Adriana; Tozatto, Eduardo; Silva, Lucienir Maria da; Donadi, Eduardo Antônio; Costa, Teresa Dalla; Lanchote, Vera Lúcia; Schmidt, Stephan; Bulitta, Jürgen B.
Source: The AAPS Journal. Unidades: FCFRP, FMRP
Subjects: FARMACODINÂMICA, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Carolina de Miranda et al. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, v. 19, n. 6, p. 1814-1825, 2017Tradução . . Disponível em: https://doi.org/10.1208/s12248-017-0138-9. Acesso em: 09 nov. 2024.
APA
Silva, C. de M., Rocha, A., Tozatto, E., Silva, L. M. da, Donadi, E. A., Costa, T. D., et al. (2017). Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, 19( 6), 1814-1825. doi:10.1208/s12248-017-0138-9
NLM
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1208/s12248-017-0138-9
Vancouver
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1208/s12248-017-0138-9
Artigo de periodico
Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics (2016)
Silva, Carolina de Miranda; Rocha, Adriana; Tozatto, Eduardo; Silva, Lucienir Maria da; Donadi, Eduardo Antônio; Lanchote, Vera Lúcia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: MOLÉCULA, ANTI-INFLAMATÓRIOS, FARMACOCINÉTICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Carolina de Miranda et al. Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, v. 120, p. 120-126, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2015.12.009. Acesso em: 09 nov. 2024.
APA
Silva, C. de M., Rocha, A., Tozatto, E., Silva, L. M. da, Donadi, E. A., & Lanchote, V. L. (2016). Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 120, 120-126. doi:10.1016/j.jpba.2015.12.009
NLM
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Lanchote VL. Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2016 ; 120 120-126.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jpba.2015.12.009
Vancouver
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Lanchote VL. Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2016 ; 120 120-126.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jpba.2015.12.009
Artigo de periodico
Sensitive method for determination of piplartine, an alkaloid amide from Piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry (2012)
Bezerra, Daniel P.; Pessoa, Cláudia; Moraes, Manoel O.; Costa-Lotufo, Letícia Veras ; Gouvea, Dayana Rubio; Jabor, Valquíria A. Polisel; Lopes, Norberto Peporine; Borges, Keyller Bastos; Lima, Mary Anne S.; Silveira, Edilberto R.
Source: Química Nova. Unidade: FCFRP
Subjects: PIPERALES, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BEZERRA, Daniel P. et al. Sensitive method for determination of piplartine, an alkaloid amide from Piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry. Química Nova, v. 35, n. 3, p. 460-465, 2012Tradução . . Disponível em: https://doi.org/10.1590/S0100-40422012000300004. Acesso em: 09 nov. 2024.
APA
Bezerra, D. P., Pessoa, C., Moraes, M. O., Costa-Lotufo, L. V., Gouvea, D. R., Jabor, V. A. P., et al. (2012). Sensitive method for determination of piplartine, an alkaloid amide from Piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry. Química Nova, 35( 3), 460-465. doi:10.1590/S0100-40422012000300004
NLM
Bezerra DP, Pessoa C, Moraes MO, Costa-Lotufo LV, Gouvea DR, Jabor VAP, Lopes NP, Borges KB, Lima MAS, Silveira ER. Sensitive method for determination of piplartine, an alkaloid amide from Piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry [Internet]. Química Nova. 2012 ; 35( 3): 460-465.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1590/S0100-40422012000300004
Vancouver
Bezerra DP, Pessoa C, Moraes MO, Costa-Lotufo LV, Gouvea DR, Jabor VAP, Lopes NP, Borges KB, Lima MAS, Silveira ER. Sensitive method for determination of piplartine, an alkaloid amide from Piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry [Internet]. Química Nova. 2012 ; 35( 3): 460-465.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1590/S0100-40422012000300004
Artigo de periodico
Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers (2010)
Rocha, Adriana; Coelho, Eduardo Barbosa; Sampaio, Stefânia Amaral; Lanchote, Vera Lúcia
Source: British Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assunto: FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Adriana et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. British Journal of Clinical Pharmacology, v. 70, n. 1, p. 43-51, 2010Tradução . . Disponível em: https://doi.org/10.1111/j.1365-2125.2010.03649.x. Acesso em: 09 nov. 2024.
APA
Rocha, A., Coelho, E. B., Sampaio, S. A., & Lanchote, V. L. (2010). Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. British Journal of Clinical Pharmacology, 70( 1), 43-51. doi:10.1111/j.1365-2125.2010.03649.x
NLM
Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers [Internet]. British Journal of Clinical Pharmacology. 2010 ; 70( 1): 43-51.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1111/j.1365-2125.2010.03649.x
Vancouver
Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers [Internet]. British Journal of Clinical Pharmacology. 2010 ; 70( 1): 43-51.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1111/j.1365-2125.2010.03649.x
Trabalho de evento-resumo
Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers (2008)
Rocha, Adriana; Coelho, Eduardo Barbosa; Sampaio, S. A.; Lanchote, Vera Lúcia
Source: Abstracts. Conference titles: World Conference on Clinical Pharmacology and Therapeutics. Unidades: FCFRP, FMRP
Assunto: FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Adriana et al. Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers. 2008, Anais.. Quebec: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, 2008. . Acesso em: 09 nov. 2024.
APA
Rocha, A., Coelho, E. B., Sampaio, S. A., & Lanchote, V. L. (2008). Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers. In Abstracts. Quebec: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo.
NLM
Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers. Abstracts. 2008 ;[citado 2024 nov. 09 ]
Vancouver
Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers. Abstracts. 2008 ;[citado 2024 nov. 09 ]

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration